More Clinical Articles


Risk Sharing Agreements on the American Horizon

Danielle Barron, (Apr 16, 2015)

US stakeholders are beginning to consider risk sharing agreements, but to what effect?

Alzheimer’s: Can we save the world from a public health disaster?

Zuzanna Fimińska, (Apr 2, 2015)

Alzheimer’s disease is a ticking time bomb for public health around the world. If we don’t act now, it will single-handedly devastate global healthcare systems.

Partnership: The Game Changer in Alzheimer’s Research

Danielle Barron, (Apr 1, 2015)

A unique public-private partnership aims to change the face of Alzheimer’s dementia research by avoiding the duplication of research efforts. Danielle Barron speaks to those involved to find out why this new approach may finally lead to effective treatments for the condition.

Patient Centered Clinical Trials

Dr Nicola Davies, (Mar 30, 2015)

As pharmaceutical companies compete to bring new drugs to market, there is an increasing emphasis on the need for patient centricity – to retain patient volunteers and produce quality data. We spoke to Duncan Cantor, Director of Communications, Boehringer Ingelheim, about the importance of patient centricity in clinical trials.

Time to flourish

Adam Hill, (Mar 22, 2015)

Failure is going to be part of the process with biosimilars, but for companies with an entrepreneurial spirit and a clear mindset, the rewards are also there...

GSK Clinical Trial Questionnaire: Most Valuable Patient Initiative

Adam Hill, (Mar 20, 2015)

A move towards greater patient centricity was behind GSK's desire to get systematic feedback from participants in clinical trials – and the company hopes its blueprint can be taken up by rivals.

Engineering a Culture of Innovation Part 2: Social Contracts

Dr Nicola Davies, (Mar 19, 2015)

Continuing the recent interview with Henry Doss, ecosystem architect and co-author of ‘The Rainforest Scorecard: A Practical Framework for Growing Innovation Potential', we now look more closely at the elements of engineering a culture of innovation.

Size Matters

Des Sampson, (Mar 17, 2015)

Dr Robert Langer was the recent recipient of the Queen Elizabeth Prize in Engineering, for his groundbreaking research into controlled, targeted drug delivery. eyeforpharma unravels his past achievements, discusses his present research and offers his future vision of medicine.

Right on target

Danielle Barron, (Mar 16, 2015)

US President Barack Obama recently pledged $215m for his precision medicine initiative. Danielle Barron discusses the future of precision medicine with InnVentis founder and CEO Thomas Wilckens, and examines the impact this will have on the current R&D environment.

A Good Story Can Keep an Organization Afloat

Dr Nicola Davies, (Mar 10, 2015)

Everyone likes a good story, but do they really have a place within pharma? We spoke to Ian Sanders, Creative Consultant and Business Storyteller, to find out.